top of page

Senior Research Associate / Associate Scientist,
Cell-Based Assay Development

Boston, MA, USA

Job Type

Full Time

About the Role

TigaTx, a Boston-based startup, is seeking a highly motivated, detail-oriented, proactive Senior Research Associate/Associate Scientist to join our team. The successful candidate will support the development of IgA-based antibody therapeutics to help unleash the tumor killing power of neutrophils by testing and executing protein and cell-based immunoassays. The ideal candidate will be highly organized, efficient, and careful in their approach to science with excellent interpersonal skills and should enjoy collaborating as a team player in a fast-paced, exciting, ever-changing startup environment.

Key Responsibilities

  • Develop and execute in vitro and ex vivo cell-based functional and molecular assays

  • Perform cell culture, cell isolation and characterization from human blood and mouse tissues

  • Analyze data and present work regularly to the scientific team

  • Maintain detailed laboratory notebooks, write SOPs, and carefully document experimental design and results in a well-maintained laboratory notebook


  • BA or MS in Biology, Immunology, or similar with at least 3 years of relevant laboratory experience

  • Strong experience with cell biology and molecular techniques including multi-parameter flow cytometry, luminescence/fluorescence/absorbance plate-based assays such as ELISA/ MSD/Luminex, and qPCR

  • Expertise in tissue culture of adherent and suspension cells and proficiency with transfections and viral transductions

  • Experience with cell-based functional assays and/or immunophenotyping strongly desired

  • Ability to establish robust, reproducible experiments and troubleshoot assays

  • Eagerness to learn and implement new assays and protocols for a variety of in vitro experiments

  • Excellent oral and written communication skills

  • Outstanding organizational skills with strong attention to detail and an ability to work under pressure to meet critical timelines

  • Ability to thrive in a highly collaborative, fast-paced, team-oriented environment with colleagues from diverse disciplines

  • Must be eligible to work in the United States without sponsorship

About TigaTx

TigaTx is developing engineered IgA monoclonal antibodies to unleash the tumor killing power of neutrophils, thereby providing a new class of medicines for the treatment of cancer patients.

Neutrophils have emerged as playing an increasing role in cancer and being an important component of the tumor microenvironment. Neutrophils, including immunosuppressive neutrophils (aka PMN-MDSC), express FcαRI (CD89), the main receptor for the IgA Fc region. Opsonization of tumor cells by IgA will lead to IgA binding to the FcαRI on neutrophils, thus converting neutrophils into potent tumor killer cells.

The company was founded in 2018 based on the groundbreaking scientific work of Dr. Leusen’s lab at the University Medical Center Utrecht in the Netherlands.

TigaTx is developing its preclinical programs in stealth mode after securing substantial seed financing from an international consortium of top-tier investors.

bottom of page